Juvenescence
13
8M
10
1.86
2
0.23
1
- Areas of investment
Summary
Juvenescence is the famous Corporate Investor, which was founded in 2016. The company was established in Europe in Isle of Man. The main department of described Corporate Investor is located in the Douglas.
This organization was formed by Declan Doogan, Greg Bailey, Jim Mellon.
The top amount of exits for fund were in 2018. Comparing to the other companies, this Juvenescence performs on 19 percentage points less the average number of lead investments. The common things for fund are deals in the range of 5 - 10 millions dollars. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually. Speaking about the real fund results, this Corporate Investor is 10 percentage points more often commits exit comparing to other organizations.
The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the Juvenescence, startups are often financed by Jim Mellon, KIZOO, John Mauldin. The meaningful sponsors for the fund in investment in the same round are WuXi AppTec, Pavilion Capital, Longevity Vision Fund. In the next rounds fund is usually obtained by Longevity Vision Fund, Sinovation Ventures, Qiming Venture Partners.
Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Genetics, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Insilico Medicine, AgeX Therapeutics, BHB Therapeutics.
Investments analytics
Analytics
- Total investments
- 13
- Lead investments
- 2
- Exits
- 1
- Rounds per year
- 1.86
- Follow on index
- 0.23
- Investments by industry
- Biotechnology (12)
- Pharmaceutical (4)
- Medical (4)
- Health Care (4)
- Therapeutics (3) Show 5 more
- Investments by region
-
- United States (11)
- China (1)
- Isle of Man (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 4
- Group Appearance index
- 0.38
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Morphoceuticals | 23 Jan 2023 | Biotechnology, Health Care, Medical, Life Science | Seed | 8M | United States, Massachusetts, Marblehead |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.